Nymox Pharmaceutical Corp
NYMX
NYMX was delisted on the 6th of July, 2023.
41 hedge funds and large institutions have $14.3M invested in Nymox Pharmaceutical Corp in 2017 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 21 increasing their positions, 8 reducing their positions, and 7 closing their positions.
163% more repeat investments, than reductions
Existing positions increased: 21 | Existing positions reduced: 8
0.15% more ownership
Funds ownership: 7.74% → 7.89% (+0.15%)
8% less capital invested
Capital invested by funds: $15.5M → $14.3M (-$1.21M)
9% less funds holding
Funds holding: 45 → 41 (-4)
57% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 7
89% less call options, than puts
Call options by funds: $201K | Put options by funds: $1.87M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$390K |
| 2 |
State Street
Boston,
Massachusetts
|
+$203K |
| 3 |
Simplex Trading
Chicago,
Illinois
|
+$167K |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$159K |
| 5 |
Morgan Stanley
New York
|
+$91.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FDCDDQ
Federation des caisses Desjardins du Quebec
Levis,
Quebec, Canada
|
-$148K |
| 2 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$76K |
| 3 |
NFA
Nationwide Fund Advisors
Columbus,
Ohio
|
-$60K |
| 4 |
Goldman Sachs
New York
|
-$53K |
| 5 |
NPC
National Planning Corporation
El Segundo,
California
|
-$42K |
NYMX Hedge Fund Activity: Q4 2017 in Review
41 of the 4,419 institutional investors tracked by Wall St. Rank reported a position in Nymox Pharmaceutical Corp (NYMX) for Q4 2017, worth a combined $14.3M — down 7.8% from $15.5M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of NYMX and 3 opened new positions — a net loss of 4 holders — while 8 trimmed existing stakes and 21 added.
The largest buyer was Susquehanna International Group, adding an estimated $390K. The largest seller was Federation des caisses Desjardins du Quebec, cutting an estimated $148K.
- 41 institutional investors held Nymox Pharmaceutical Corp (NYMX) as of Q4 2017, down from 45 in Q3 2017.
- Funds reported $14.3M of Nymox Pharmaceutical Corp stock for Q4 2017, down 7.8% quarter-over-quarter.
- 3 funds opened new Nymox Pharmaceutical Corp positions in Q4 2017 and 7 closed out, a net change of -4 holders.
- The largest Nymox Pharmaceutical Corp buyer in Q4 2017 was Susquehanna International Group, an estimated $390K added.
- The largest Nymox Pharmaceutical Corp seller in Q4 2017 was Federation des caisses Desjardins du Quebec, an estimated $148K sold.
Based on aggregated 13F filings for Q4 2017.